INNUREX

Welcome to the Brand page for “INNUREX”, which is offered here for In the heading, delete class 42. statement(s): column 2, line 2, after technologies in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and disease column 2, line 4, after products in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and disease column 2, line 13 after vascularisation in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and disease should be inserted.;gene therapy and prophylaxis products, pharmaceutical substances and preparations for use in the medical industry, vaccines, enzymes and enzyme preparations, anti-apoptopic and angiostatic/angiogenic molecules, retroviral vector and retroviral vector manufacturing preparations, all for use in gene delivery technologies in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and disease; vector production technologies and neurogenomics products in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and disease; chemical products for use in medical science for the treatment of diseases of the eye, vascular and neo-vascularisition disorders, single gene disorders, cancer, diseases of the nervous system, inflammatory and auto-immune diseases, blood disorders, vascular disorders and disorders arising from inappropriate vascularisation *and injuries of the nervous, system all* in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and disease; pharmaceutical and biochemical preparations for the treatment of damaged nerves and spinal injuries and for the induction of nerve re-growth; medical instruments and apparatus for the administration of gene and antibody-based therapy and prophylactics, preparations and substances, pre-filled vials, syringes and injectors for medical purposes, all in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and disease;in the statement, page 2, column 1, line 15, after vascularisation and injuries of the nervous, system, all should be inserted.;chemical and biochemical products for use in gene delivery technology, enzymes and chemicals for in vitro use in laboratories and for analysis in gene delivery technology, enzymes and chemicals for in vitro use in laboratories and for analysis in gene delivery technology, micro-organisms, cell cultures, plasmids and cultures of micro-organisms, deoxyribonucleic acid sequences, cloning vehicles and recombinant deoxyribonucleic variations thereof, all for in vivo use in gene delivery technology and catalysts for gene delivery technology in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and disease;.

Its status is currently believed to be active. Its class is unavailable. “INNUREX” is believed to be currently owned by “Oxford BioMedica plc”.